# Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC

> **NCT07247227** · NA · RECRUITING · sponsor: **Peking Union Medical College** · enrollment: 150 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Sugemalimab and Chemotherapy

## Key facts

- **NCT ID:** NCT07247227
- **Lead sponsor:** Peking Union Medical College
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-10
- **Primary completion:** 2027-05
- **Final completion:** 2027-05
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07247227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07247227, "Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07247227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*